PC3 is a cell line characteristic of prostatic small cell carcinoma.
about
P1343
MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cellsCalcium Ion Flow Permeates Cells through SOCs to Promote Cathode-Directed GalvanotaxisCombined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsA dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cellsCombined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infectionReal-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting.Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide.The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells.Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression.Two New Oxodolastane Diterpenes from the Jamaican Macroalga Canistrocarpus cervicornis.Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonizationOptimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells.Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivitySpecific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contextsIn vitro and in vivo model systems used in prostate cancer research.Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: Role of nitric oxide.Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cellsEstrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents.Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancerHSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancerSRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine CarcinomaMetastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features.miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.Modeling a lethal prostate cancer variant with small-cell carcinoma features.Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor CellsReview of small cell carcinomas of the prostate.Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cellsFOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.Statin derivatives as therapeutic agents for castration-resistant prostate cancer.DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.Identification of infusion strategy for achieving repeatable nanoparticle distribution and quantification of thermal dosage using micro-CT Hounsfield unit in magnetic nanoparticle hyperthermia.Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.A biomimetic approach to hormone resistant prostate cancer cell isolation using inactivated Sendai virus (HVJ-E).
P2860
Q21134916-28E1BE9C-AF38-4187-B1F2-2061BFD863C8Q27314912-8B47693F-746D-4457-B81B-7AF1607C8E2BQ28484572-A198C3E7-B462-4D46-912A-1DF087157C0CQ28545928-DB2ADAE1-1E88-42E0-998F-4507CE2EA924Q28573536-A38F5D0E-5939-4B6E-8B27-0C372E19886DQ28817152-A1518776-3614-4B9F-BA3E-F53D2EFB4403Q30378832-6CF7FE6C-D799-4DB5-8CC4-05D8DDA832C9Q33650423-F38507C1-D37D-4AFF-A7D4-421A071FEADFQ33660177-DF340E2E-F741-4AE7-AE44-4D2E48C4B2B5Q33739134-18BA2D86-23A9-4A1C-9AA1-24171D7D8E60Q33833290-3C9756DE-B0FB-4616-B798-1FE8CA034779Q35108922-73EA2496-498C-45D6-803E-5FA9E7280B2EQ35133088-C62999F1-F0C0-4567-A2DC-F3F94670A1CAQ35176093-F1C34803-77A9-4380-96A3-43D83EDAE05BQ35741647-503A1115-0DD4-432E-847C-478CC1D9FF16Q35806390-2C4C1834-8875-47AF-AE52-073438FBE26EQ35984270-8E16FD65-47DF-42ED-85E3-1D9D9E3EDE0BQ36028196-E2551132-1E80-487B-BBA2-35003F61D26AQ36077063-7440933B-6F35-4147-8B40-20B5B47AAC5BQ36206304-3D6B3666-0A2C-4DD8-830B-8B34DF0949E0Q36296850-F10E9A2C-869E-426B-B11E-75263C57564AQ36402883-B7A77D61-8A0E-4993-B859-7F9A031C2D63Q36416400-24788F8C-7B86-464E-98AE-449CD694C989Q36545260-72003CF5-FAE0-483C-B895-1407AA09CD12Q36688923-036FE4DD-9659-4DCF-8EEC-4C042441E359Q36805567-C5FD234D-807B-4D34-83E4-D65E5BF0D261Q37377562-6AFBE4C9-5555-46C8-A317-1CB4BEBC8700Q37457859-0E2C4BA3-1D6A-4E77-AE71-125FA99F283AQ37529983-BAD81E73-47CF-49F5-B6B8-2DDEA1D03B00Q37582049-342E1844-6842-4ED5-AD85-E63526707C67Q37611641-DCF2A033-9F6F-4442-BED6-3AB89F0AE796Q37960020-4C754C24-427A-42A5-BB68-1A844B5AA674Q38722639-3B872ECD-A6AB-4ED1-96D6-E657A57E7EC5Q38722718-E9E87368-5D5F-42E1-8D31-BC474037AEFBQ38735989-C4D7A11C-C020-476B-933C-2F5FD562F494Q38743845-7817DF45-4141-4C34-B659-3DBC5B2D7478Q38763212-8C6EF3BA-13D2-4514-B68E-F736C05BCDA0Q38804366-F73AF530-A788-4A4F-B491-DFD9554CD705Q38815759-C9684CED-B8A9-47F5-88F8-000E7914E0E9Q38820595-3F802006-2747-4B83-B9C7-51F0F2E734F4
P2860
PC3 is a cell line characteristic of prostatic small cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@ast
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@en
type
label
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@ast
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@en
prefLabel
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@ast
PC3 is a cell line characteristic of prostatic small cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
PC3 is a cell line characteristic of prostatic small cell carcinoma
@en
P2093
Chao-Zhao Liang
Hong Zhang
Jiaoti Huang
Jill M Squires
P2860
P304
P356
10.1002/PROS.21383
P4510
P577
2011-03-22T00:00:00Z